You have full text access to this OnlineOpen article

Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia

  1. Masayuki Ide1,3,
  2. Tetsuo Ohnishi1,
  3. Miyuki Murayama2,
  4. Izuru Matsumoto4,
  5. Kazuo Yamada1,
  6. Yoshimi Iwayama1,
  7. Irina Dedova4,5,
  8. Tomoko Toyota1,
  9. Takashi Asada3,
  10. Akihiko Takashima2,
  11. Takeo Yoshikawa1,6

Article first published online: 20 JUL 2006

DOI: 10.1111/j.1471-4159.2006.04033.x

Issue

Journal of Neurochemistry

Journal of Neurochemistry

Volume 99, Issue 1, pages 277–287, October 2006

Additional Information

How to Cite

Ide, M., Ohnishi, T., Murayama, M., Matsumoto, I., Yamada, K., Iwayama, Y., Dedova, I., Toyota, T., Asada, T., Takashima, A. and Yoshikawa, T. (2006), Failure to support a genetic contribution of AKT1 polymorphisms and altered AKT signaling in schizophrenia. Journal of Neurochemistry, 99: 277–287. doi: 10.1111/j.1471-4159.2006.04033.x

Author Information

  1. 1

    Laboratory for Molecular Psychiatry,

  2. 2

    Laboratory for Alzheimer's Disease, RIKEN Brain Science Institute, Saitama, Japan

  3. 3

    Department of Psychiatry, University of Tsukuba School of Medicine, Ibaraki, Japan

  4. 4

    Department of Pathology, University of Sydney & NSW, Australia

  5. 5

    Neuroscience Institute of Schizophrenia and Allied Disorders, Sydney, Australia

  6. 6

    CREST, Japan Science and Technology Agency, Saitama, Japan

*Address correspondence and reprint requests to Takeo Yoshikawa MD PhD, Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, 2–1 Hirosawa, Wako-city, Saitama 351–0198, Japan. E-mail: takeo@brain.riken.go.jp

Publication History

  1. Issue published online: 20 JUL 2006
  2. Article first published online: 20 JUL 2006
  3. Received April 25, 2006; revised manuscript received May 31, 2006; accepted June 1, 2006.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (933K)

References

  • American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn (DSM-IV). American Psychiatric Association, Washington DC.
  • Andjelkovic M., Jakubowicz T., Cron P., Ming X. F., Han J. W. and Hemmings B. A. (1996) Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc. Natl Acad. Sci. USA 93, 5699–5704.
  • Aoki-Suzuki M., Yamada K., Meerabux J. et al. (2005) A family–based association study and gene expression analyses of netrin-G1 and – G2 genes in schizophrenia. Biol. Psychiatry 57, 382–393.
  • Barbeau D., Liang J. J., Robitalille Y., Quirion R. and Srivastava L. K. (1995) Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains. Proc. Natl Acad. Sci. USA 92, 2785–2789.
  • Beasley C., Cotter D. and Everall I. (2002) An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr. Res. 58, 63–67.
  • Beaulieu J. M., Sotnikova T. D., Yao W. D., Kockeritz L., Woodgett J. R., Gainetdinov R. R. and Caron M. G. (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl Acad. Sci. USA 101, 5099–5104.
  • Beaulieu J. M., Sotnikova T. D., Marion S., Lefkowitz R. J., Gainetdinov R. R. and Caron M. G. (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261–273.
  • Beffert U., Morfini G., Bock H. H., Reyna H., Brady S. T. and Herz J. (2002) Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3beta. J. Biol. Chem. 277, 49 958–49 964.
  • Clayton D. (1999) A generalization of the transmission/disequilibrium test for uncertain-haplotype transmission. Am. J. Hum. Genet. 65, 1170–1177.
  • Conti L., Sipione S., Magrassi L. et al. (2001) Shc signaling in differentiating neural progenitor cells. Nat. Neurosci. 4, 579–586.
  • Cross D. A., Alessi D. R., Cohen P., Andjelkovich M. and Hemmings B. A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785–789.
  • De Ferrari G. V., Chacón M. A., Barría M. I., Garrido J. L., Godoy J. A., Olivares G., Reyes A. E., Alvarez A., Bronfman M. and Inestrosa N. C. (2003) Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol. Psychiatry 8, 195–208.
  • Dudbridge F. (2003) Pedigree disequilibrium tests for multilocus haplotypes. Genet. Epidemiol. 25, 115–121.
    Direct Link:
  • Dudek H., Datta S. R., Franke T. F., Birnbaum M. J., Yao R., Cooper G. M., Segal R. A., Kaplan D. R. and Greenberg M. E. (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275, 661–665.
  • Emamian E. S., Hall D., Birnbaum M. J., Karayiorgou M. and Gogos J. A. (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet. 36, 131–137.
  • Goedert M., Cohen E. S., Jakes R. and Cohen P. (1992) p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease. FEBS Lett. 312, 95–99.
  • Iitaka C., Miyazaki K., Akaike T. and Ishida N. (2005) A role for glycogen synthase kinase-3beta in the mammalian circadian clock. J. Biol. Chem. 280, 29 397–29 402.
  • Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., Inada T. and Ozaki N. (2004) Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol. Psychiatry 56, 698–700.
  • Ilia M., Beasley C., Meijer D., Kerwin R., Cotter D., Everall I. and Price J. (2002) Expression of Oct – 6, a POU III domain transcription factor, in schizophrenia. Am. J. Psychiatry 159, 1174–1182.
  • Impagnatiello F., Guidotti A. R., Pesold C. et al. (1998) A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl Acad. Sci. USA 95, 15 718–15 723.
  • Ishiguro K., Sato K., Takamatsu M., Park J., Uchida T. and Imahori K. (1995) Analysis of phosphorylation of tau with antibodies specific for phosphorylation sites. Neurosci. Lett. 202, 81–84.
  • Keks N., Hill C., Opeskin K., Copolov D. and Dean B. (1999) Psychiatric diagnosis after death: the problems of accurate diagnosis, in The Use of CNS Autopsy Tissue in Psychiatric Research: a Practical Guide (DeanB., HydeT. M. and KleinmanJ., eds.), pp. 19–37. Gordon and Breach Science Publishers, Sydney.
  • Kozlovsky N., Belmaker R. H. and Agam G. (2000) Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am. J. Psychiatry 157, 831–833.
  • Kozlovsky N., Belmaker R. H. and Agam G. (2002) GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur. Neuropsychopharmacol. 12, 13–25.
  • Kozlovsky N., Shanon-Weickert C., Tomaskovic-Crook E., Kleinman J. E., Belmaker R. H. and Agam G. (2004) Reduced GSK-3beta mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients. J. Neural. Transm. 111, 1583–1592.
  • Li J. Z., Vawter M. P., Walsh D. M. et al. (2004) Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum. Mol. Genet. 13, 609–616.
  • Li X., Friedman A. B., Roh M. S. and Jope R. S. (2005) Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain. J. Neurochem. 92, 701–704.
    Direct Link:
  • Liu Y. L., Fann C. S., Liu C. M. et al. (2006) Absence of significant associations between four AKT1 SNP markers and schizophrenia in the Taiwanese population. Psychiatr. Genet. 16, 39–41.
  • Markus A., Zhong J. and Snider W. D. (2002) Raf and akt mediate distinct aspects of sensory axon growth. Neuron 35, 65–76.
  • Martin E. R., Monks S. A., Warren L. L. and Kaplan N. L. (2000) A test for linkage and association in general pedigrees: the pedigree disequilibrium test. Am. J. Hum. Genet. 67, 146–154.
  • Martinek S., Inonog S., Manoukian A. S. and Young M. W. (2001) A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 105, 769–779.
  • Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Titani K. and Ihara Y. (1995) Proline-directed and non-proline-directed phosphorylation of PHF-tau. J. Biol. Chem. 270, 823–829.
  • O'Connell J. R. and Weeks D. E. (1998) PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am. J. Hum. Genet. 63, 259–266.
  • Ohnuma T., Kato H., Arai H., McKenna P. J. and Emson P. C. (2003) Expression of Fyn, a non-receptor tyrosine kinase in prefrontal cortex from patients with schizophrenia and its correlation with clinical onset. Brain Res. Mol. Brain Res. 112, 90–94.
  • Ohtsuki T., Inada T. and Arinami T. (2004) Failure to confirm association between AKT1 haplotype and schizophrenia in a Japanese case-control population. Mol. Psychiatry 9, 981–983.
  • Planel E., Miyasaka T., Launey T., Chui D. H., Tanemura K., Sato S., Murayama O., Ishiguro K., Tatebayashi Y. and Takashima A. (2004) Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J. Neurosci. 24, 2401–2411.
  • Sato S., Tatebayashi Y., Akagi T. et al. (2002) Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J. Biol. Chem. 277, 42 060–42 065.
  • Schwab S. G., Hoefgen B., Hanses C., Hassenbach M. B., Albus M., Lerer B., Trixler M., Maier W. and Wildenauer D. B. (2005) Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol. Psychiatry 58, 446–450.
  • Sham P. C. and Curtis D. (1995) Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann. Hum. Genet. 59, 97–105.
    Direct Link:
  • Takahashi M., Shirakawa O., Toyooka K. et al. (2000) Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol. Psychiatry 5, 293–300.
  • Torrey E. F., Webster M., Knable M., Johnston N. and Yolken R. H. (2000) The stanley foundation brain collection and neuropathology consortium. Schizophr. Res. 44, 151–155.
  • Toyota T., Yamada K., Detera-Wadleigh S. D. and Yoshikawa T. (2003) Analysis of a cluster of polymorphisms in AKT1 gene in bipolar pedigrees: a family–based association study. Neurosci. Lett. 339, 5–8.
  • Weinberger D. R. (1996) On the plausibility of ‘the neurodevelopmental hypothesis’ of schizophrenia. Neuropsychopharmacology 14, 1S–11S.
  • Yamada K., Iwayama-Shigeno Y., Yoshida Y., Toyota T., Itokawa M., Hattori E., Shimuzu H. and Yoshikawa T. (2004) Family–based association study of schizophrenia with 444 markers and analysis of a new susceptibility locus mapped to 11q13.3. Am. J. Med. Genet. 127B, 11–19.
    Direct Link:
View Full Article (HTML) Get PDF (933K)